Free Intensive Nov 21–22Free 2-day hands-on Vibecoding Intensive on Nov 21–22 at 16:00 MSK (Sat–Sun) · Live Cohort 3 starts Nov 23Join Free →Cohort 3 (Nov 23)
IndustryInsight · On RadarTNW→ original

MegaRobo Raises Nearly $200M for Robotic Labs Where AI Runs the Experiments

AI already reads papers and predicts molecules, but a hypothesis still has to be tested in a real lab. China's MegaRobo has raised nearly $200M for systems where a model plans an experiment, hands it to robots, and picks the next step based on the result. The company says it has more than 500 customers, mostly in pharma and biotech. For agent builders, this is a signal: their next environment is the physical world.

AI-processed from TNW; edited by Hamidun News
MegaRobo Raises Nearly $200M for Robotic Labs Where AI Runs the Experiments
Source: TNW. Collage: Hamidun News.
Listen to article
Article Fact Sheet & Key Figures
ParameterDetails
Primary sourceTNW ↗
Editor-in-Chief
Key metric #1The round included Oman's sovereign fund and a new investor, CMB International
Key metric #2The Poreva Open contest will test more than 10,000 AI-designed proteins in the lab
Key metric #3In total, the company has raised about $600M, including a $300M Series C in 2022

Neural networks have learned to read scientific papers and predict molecular properties, but science has an awkward constraint: every prediction eventually has to be checked by hand in a lab. That gap between a digital hypothesis and a real experiment is what China's MegaRobo Technologies is targeting. The company, which automates laboratories, has raised nearly $200M so that AI can set up experiments on its own.

What MegaRobo does and who invested

The round included the Oman Investment Authority, the country's sovereign fund, and a new investor, CMB International. Previous investors Asia Investment Capital, Granite Asia and Sinovation Ventures also put in money. The company has not disclosed its valuation.

The idea is simple to explain with an everyday example. Picture a chef who not only invents a recipe but also cooks the dish, tastes it, and decides from the flavor what to change in the next version. MegaRobo connects AI models with robots and laboratory equipment. The model plans an experiment, the robot carries it out, and the resulting data helps choose the next step. Founder and CEO Daniel Huang describes this as a shift from AI that interprets the world to AI that helps create new knowledge, materials, processes and products.

According to the company, it has more than 500 customers, mostly drug makers, biotech firms and research labs. The Megalaxy Lab platform lets scientists and AI agents submit experiment requests to robotic labs. The company says the platform has already served more than 200 users.

A protein design contest as a common benchmark

MegaRobo has also launched Poreva Open, a protein design contest run with Tencent Cloud and DNA manufacturer Twist Bioscience. Megalaxy Lab will test more than 10,000 AI-generated proteins in a real lab. The goal is a shared benchmark built not on calculations and simulations, but on actual laboratory results.

For the industry, this is an important detail. In protein and drug design, many models look good on paper, yet they are hard to compare: each team has its own data and its own validation methods. A single physical test on a large sample makes it possible to compare approaches fairly. Others are taking a similar route: the article notes that Anthropic brought in external labs to test Claude.

Market and plans

MegaRobo operates amid heavy interest in AI for drug development. Isomorphic Labs, owned by Alphabet, and Chai Discovery have also raised large rounds, and Berlin-based Dunia Innovations is building its own platform. The source text does not give the amounts of those deals, so scale can only be compared qualitatively.

In total, MegaRobo has raised about $600M, including a $300M Series C in 2022 with participation from Goldman Sachs. The new money will go toward expansion into North America, Europe, the Middle East and Asia. The company also wants to apply the same technology beyond science.

What this means for practitioners

First, AI agents get another environment to work in: not a browser or a code repository, but a physical experiment with a measurable result. A model that chooses the next experiment based on the previous data runs the same action-feedback loop familiar to anyone building agents, except that each iteration costs reagents and robot time.

Second, the limitations are clear. The company has not disclosed its valuation, revenue, or data on how often AI planning actually speeds up discoveries. The figures of 500 customers and 200 Megalaxy Lab users are MegaRobo's own claims and have not been independently verified. The results of the Poreva Open contest will show whether the approach works in practice.

Third, for product managers and founders, this is a sign that demand for "AI plus physical automation" is backed by real money, including from state funds. If your product touches science, pharma or materials, it is worth thinking early about how to connect to such cloud labs through APIs and agents, not only to language models.

Story

Key Questions Answered

What MegaRobo does and who invested?

The round included the Oman Investment Authority, the country's sovereign fund, and a new investor, CMB International. Previous investors Asia Investment Capital, Granite Asia and Sinovation Ventures also put in money. The company has not disclosed its valuation. The idea is simple to explain with an everyday example. Picture a chef who not only invents a recipe but also cooks the dish, tastes it, and decides from the flavor what to change in the next version.

What are the key details on A protein design contest as a common benchmark?

MegaRobo has also launched Poreva Open, a protein design contest run with Tencent Cloud and DNA manufacturer Twist Bioscience. Megalaxy Lab will test more than 10,000 AI-generated proteins in a real lab. The goal is a shared benchmark built not on calculations and simulations, but on actual laboratory results. For the industry, this is an important detail. In protein and drug design, many models look good on paper, yet they are hard to compare: each team has its own data and its own validation methods.

What are the key details on Market and plans?

MegaRobo operates amid heavy interest in AI for drug development. Isomorphic Labs, owned by Alphabet, and Chai Discovery have also raised large rounds, and Berlin-based Dunia Innovations is building its own platform. The source text does not give the amounts of those deals, so scale can only be compared qualitatively. In total, MegaRobo has raised about $600M, including a $300M Series C in 2022 with participation from Goldman Sachs.

ZK
Zhemal Khamidun — CPO at Alpina Digital, product manager of AlpinaGPT. Building AI products since 2019. Hamidun News is a pet project that grew into a production aggregator with 6,000+ readers.
✦ Private AI Builders Community · Vibe Club

Ship AI Faster with Founders, Engineers & Weekly Architecture Reviews

Inside Vibe Club (hamidun.com/club) — weekly live masterminds with Zhemal Khamidun, Tech Radar, full LMS access, and 370+ production Claude Code skills.

Join Vibe Club →Explore Hamidun Academy
What do you think?
Loading comments…